Surveillance Study for HCC by Combining Biomarkers With Imaging (ALDUS)

Exclusion Criteria

• •Patients with liver cancer at the time of enrollment
• •Patients who have experienced HCC or other malignant tumor with in five (5) years
• •Women with pregnancies
• •Patients who are likely to be transplanted within one (1) year
• •Patients with ≥ 3 mg/dL of total bilirubin
• •Patients with uncontrollable ascites
• •Patients with ≥ Grade II of hepatic encephalopathy